Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemiaMayumi Sugita, Mónica L. Guzmán, David Wilkes et al.|npj Precision Oncology|2021Cited by 36
A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized studyAgnieszka Wierzbowska, Gail J. Roboz, Magdalena Dutka et al.|Blood|2025Cited by 1
Metadata record for the manuscript: Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid LeukemiaMayumi Sugita, Mónica L. Guzmán, David Wilkes et al.|Figshare|2021Cited by 1
A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)Agnieszka Wierzbowska, Gail J. Roboz, Anna Czyż et al.|Blood|2022Cited by 0
Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 StudyAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2022Cited by 0